CN105412535B - 一种治疗感冒的药物组合物在制备抗菌的药物中的应用 - Google Patents
一种治疗感冒的药物组合物在制备抗菌的药物中的应用 Download PDFInfo
- Publication number
- CN105412535B CN105412535B CN201510866699.4A CN201510866699A CN105412535B CN 105412535 B CN105412535 B CN 105412535B CN 201510866699 A CN201510866699 A CN 201510866699A CN 105412535 B CN105412535 B CN 105412535B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- preparation
- mint
- ephedra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 229940124350 antibacterial drug Drugs 0.000 title claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 47
- 241000218671 Ephedra Species 0.000 claims abstract description 30
- 239000008187 granular material Substances 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 23
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 23
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 23
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 17
- 241000931705 Cicada Species 0.000 claims abstract description 17
- 241000935235 Fritillaria meleagris Species 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 14
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 14
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 13
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 13
- 235000011477 liquorice Nutrition 0.000 claims abstract description 13
- 239000006187 pill Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 239000007924 injection Substances 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims abstract description 4
- 239000007901 soft capsule Substances 0.000 claims abstract description 3
- 238000013268 sustained release Methods 0.000 claims abstract 2
- 239000012730 sustained-release form Substances 0.000 claims abstract 2
- 238000002156 mixing Methods 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 239000000341 volatile oil Substances 0.000 claims description 31
- 229920001353 Dextrin Polymers 0.000 claims description 23
- 239000004375 Dextrin Substances 0.000 claims description 23
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 23
- 229930006000 Sucrose Natural products 0.000 claims description 23
- 235000019425 dextrin Nutrition 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 21
- 239000005720 sucrose Substances 0.000 claims description 20
- 239000007864 aqueous solution Substances 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 16
- 241000607762 Shigella flexneri Species 0.000 claims description 16
- 244000018633 Prunus armeniaca Species 0.000 claims description 15
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 13
- 238000001256 steam distillation Methods 0.000 claims description 13
- 230000000844 anti-bacterial effect Effects 0.000 claims description 10
- 238000005507 spraying Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 244000144725 Amygdalus communis Species 0.000 abstract description 2
- 235000003893 Prunus dulcis var amara Nutrition 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 241000588724 Escherichia coli Species 0.000 description 26
- 229960004793 sucrose Drugs 0.000 description 22
- 241000588769 Proteus <enterobacteria> Species 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 21
- 241000191967 Staphylococcus aureus Species 0.000 description 18
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 14
- 235000013305 food Nutrition 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 239000012530 fluid Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000845 anti-microbial effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 108010011485 Aspartame Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 235000010357 aspartame Nutrition 0.000 description 9
- 239000000605 aspartame Substances 0.000 description 9
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 9
- 229960003438 aspartame Drugs 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 239000001116 FEMA 4028 Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000005374 Poisoning Diseases 0.000 description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 5
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 5
- 229960004853 betadex Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 231100000572 poisoning Toxicity 0.000 description 5
- 230000000607 poisoning effect Effects 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 241000208365 Celastraceae Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000000336 Solanum dulcamara Nutrition 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 235000006751 Platycodon Nutrition 0.000 description 3
- 241000357613 Platycodon Species 0.000 description 3
- 241000207929 Scutellaria Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229930189914 platycodon Natural products 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- 235000007716 Citrus aurantium Nutrition 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002416 diarrheagenic effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000021190 leftovers Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗感冒的药物组合物在制备抗菌的药物中的应用，所述药物组合物的原料药组成为：麻黄1‑9重量份，薄荷1‑9重量份，蝉蜕1‑9重量份，金银花1‑20重量份，黄芩2‑20重量份，苦杏仁2‑18重量份，浙贝母1‑9重量份，桔梗1‑9重量份，甘草1‑9重量份；取上述原料药，加入常规辅料，按照常规工艺，制成临床可接受的片剂、颗粒剂、丸剂、胶囊剂、滴丸、软胶囊剂、缓释剂、口服液体制剂或冻干粉针剂，本发明开辟了新用途，为感染金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌的细菌治疗提供了新的药物。
Description
技术领域
本发明涉及一种治疗感冒的药物组合物的新用途，特别涉及一种治疗感冒的药物组合物在制备抗菌的药物中的应用。
背景技术
金黄色葡萄球菌的流行病学一般有如下特点：季节分布，多见于春夏季；中毒食品种类多，如奶、肉、蛋、鱼及其制品。此外，剩饭、油煎蛋、糯米糕及凉粉等引起的中毒事件也有报道。上呼吸道感染患者鼻腔带菌率83％，所以人畜化脓性感染部位，常成为污染源。金黄色葡萄球菌是人类化脓感染中最常见的病原菌，可引起局部化脓感染，也可引起肺炎、伪膜性肠炎、心包炎等，甚至败血症、脓毒症等全身感染。
大肠埃希菌，俗名大肠杆菌(革兰氏阴性短杆菌)，周身鞭毛，能运动，无芽。是人和动物肠道中的正常栖居菌。大肠埃希菌的致病物质之一是血浆凝固酶。根据致病性的不同，致泻性大肠埃希菌被分为产肠毒素性大肠埃希菌、肠道侵袭性大肠埃希菌、肠道致病性大肠埃希菌、肠集聚性黏附性大肠埃希菌和肠出血性大肠埃希菌5种。部分埃希菌菌株与婴儿腹泻有关，并可引起成人腹泻或食物中毒的暴发。肠出血性大肠埃希菌O157：H7是导致1996年日本食物中毒暴发的罪魁祸首，它是出血性大肠埃希菌中的致病性血清型，主要侵犯小肠远端和结肠。常见中毒食品为各类熟肉制品、冷荤、牛肉、生牛奶，其次为蛋及蛋制品、乳酪及蔬菜、水果、饮料等食品。中毒原因主要是受污染的食品食用前未经彻底加热。中毒多发生在3、9月。
铜绿假单胞菌是存在于人类中最常见的一种假单胞菌，它偶尔可在腋下和肛门生殖道周围的正常皮肤，但除非给服抗生素，在粪中甚为罕见。该菌通常伴随毒力较强的细菌存在于病灶中，但偶尔也可单独引起暴露于外部的组织感染。感染通常发生于医院内，洗涤槽、防腐溶液和贮尿容器中常可发现这种细菌。通过医护人员可将病菌传给病人，特别在灼伤和新生儿重症监护室。是重要的医院内病原菌。
福氏志贺氏菌，通称福氏痢疾杆菌。发酵甘露醇。有15个血清型(含亚型及变种)，抗原构造复杂，有群抗原和型抗原。根据型抗原的不同，分为6型，又根据群抗原的不同将型分为亚型；X、Y变种没有特异性抗原，仅有不同的群抗原。我国以福氏和宋内志贺菌引起的菌痢最为常见。细菌性痢疾是一种常见病，主要流行于发展中国家，全世界年病例数超过2亿，其中500万例需住院治疗，年死亡病例达65万。志贺菌属还可感染除人类以外的其他灵长类，偶尔感染畜禽，可引起肉品等污染。
变形杆菌在自然界分布广泛，在土壤、污水和垃圾中可检测出该菌，亦可寄生于人和动物的肠道，食品受其污染的机会很多。生的肉类食品，尤其动物内脏变形杆菌带菌率较高，在食品烹调加工过程中，处理生、熟食品的工具、容器未严格分开，被污染的食品工具、容器则可污染熟制品。受变形杆菌污染的食品在较高温度下存放较长的时间，细菌大量生长繁殖，食用前未加热或加热不彻底，食后即引起中毒。变形杆菌常与其他腐败菌共同污染生食品，使生食品发生感官上的改变，但熟制品被变形杆菌污染通常无感官性状的变化，极易被忽视而引起中毒。
目前，人们预防病毒一般都是利用疫苗，但是这种方法并不是最为有效的方法，而且也不经济。病毒在侵入机体后进入细胞内繁殖，所以疫苗是无法针对那些已经进入到细胞内的病毒进行清除，病毒在这种感染过程中很有可能发生基因重组，最终导致“超级病毒”的诞生。化学性药物治疗病毒病效果甚微，这是因为一方面药物进入机体通过各种屏障作用和酶系作用，使得浓度降低很多；另一方面病毒呈严格的细胞内寄生，抗病毒药物在破坏或抑制细胞内病毒的同时，也对未感染的细胞产生了不必要损伤。此类做法存在耐药性、残留性、毒副作用大、抗病毒谱较窄等缺点，因而临床应用有限。因此，需要不断研发新的抗病毒的药物去对抗病毒来减轻大量疫苗不被利用的情况。
目前临床上通常使用抗生素来治疗细菌感染，虽然有一定的作用，但副作用以及抗生素的泛滥使用存在很大的问题和隐患。而中成药的治疗细菌感染的研究还在探索中。治疗感冒的药物比较多，但是无法确定能对哪种细菌有效果。
专利号为2009101483249，发明名称为“一种治疗感冒的药物组合物及其制备方法”的发明专利公开了一种治疗感冒的药物组合物。
本发明在前述发明专利的基础上继续对该药物组合物的药效作用进行了深入研究。
发明内容
本发明目的在于公开一种治疗感冒的药物组合物在制备抗菌的药物中的应用。为抗菌提供新的药物。
本发明所述药物组合物的原料药组成已在专利号为2009101483249，发明名称为“一种治疗感冒的药物组合物及其制备方法”的发明专利中公开，具体如下：
本发明的技术方案为：
本发明药物组合物的原料药组成为：麻黄1-9重量份，薄荷1-9重量份，蝉蜕1-9重量份，金银花1-20重量份，黄芩2-20重量份，苦杏仁2-18重量份，浙贝母1-9重量份，桔梗1-9重量份，甘草1-9重量份。
所述药物组合物的原料药组成可以优选为：
麻黄6重量份，薄荷5重量份，蝉蜕5重量份，金银花15重量份，黄芩12重量份，苦杏仁9重量份，浙贝母6重量份，，桔梗6重量份，甘草5重量份。
所述药物组合物的原料药组成还可以：
麻黄3重量份，薄荷9重量份，蝉蜕3重量份，金银花17重量份，黄芩9重量份，苦杏仁16重量份，浙贝母3重量份，桔梗8重量份，甘草4重量份。
所述药物组合物的原料药组成还可以为：
麻黄9重量份，薄荷2重量份，蝉蜕7重量份，金银花11重量份，黄芩18重量份，苦杏仁7重量份，浙贝母7重量份，桔梗4重量份，甘草8重量份。
所述药物组合物的原料药组成优选为：麻黄2.5重量份，薄荷2.08重量份，蝉蜕2.08重量份，金银花6.25重量份，黄芩5重量份，苦杏仁3.75重量份，浙贝母2.5重量份，桔梗2.5重量份，甘草2.08重量份。
取上述原料药，加入常规辅料，按照常规工艺，制成临床可接受的片剂、颗粒剂、丸剂、胶囊剂、滴丸、软胶囊剂、缓释剂、口服液体制剂或冻干粉针剂
优选的，本发明药物组合物的制备方法包括如下步骤：以上九味，薄荷用水蒸汽蒸馏法提取挥发油，蒸馏后的水溶液另器保存，药渣与其余麻黄等八味，加水煎煮二次，每次1小时，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.23-1.25(90-95℃)的清膏，取清膏1份，加蔗糖0.16份，糊精0.16份，混匀，制成颗粒，干燥，喷入上述挥发油，混匀，即得。
优选的，本发明药物组合物的制备方法包括如下步骤：
薄荷用水蒸气蒸馏法提取挥发油，蒸馏后的水溶液另器保存；药渣与其余麻黄等八味，加水煎煮二次，每次1小时，第1次8倍量的水，第2次6倍量的水，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为90℃时为1.18～1.20的清膏；清膏加入蔗糖1.7～2.3重量份、糊精1.7～2.3重量份，混匀、制粒、干燥、整粒，喷入挥发油，混匀，制成颗粒；或加入蔗糖1.7～2.3重量份、糊精1.7～2.3重量份，蔗糖与糊精比例为1∶1，阿司帕坦0.06重量份，混匀，制粒、干燥、整粒，混匀，制成颗粒，即得。
本发明药物组合物的制备方法还可以包括如下步骤：
薄荷用水蒸气蒸馏法提取挥发油，蒸馏后的水溶液另器保存；药渣与其余麻黄等八味，加水煎煮1-3次，每次0.5-1.5小时，首次加6-10重量倍水，第二或三次加5-8重量倍水，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度90～95℃时为1.18～1.20的清膏；所得挥发油用适量β-环糊精包结，加适量清膏调色，喷雾干燥；取清膏，加蔗糖1-3重量份，糊精1-3重量份，蔗糖与糊精比例为1∶1，混匀、制粒、干燥、整粒，将挥发油包结物加入于干颗粒中，混匀，按常规方法制成临床可接受的任何剂型，如丸剂、散剂、胶囊剂、颗粒剂、滴丸、口服液体制剂；或加入蔗糖、糊精时再加入阿司帕坦0.03-0.07重量份，混匀，制粒、干燥、整粒，混匀，制成颗粒。
所述药物组合物的制备方法还可以包括如下步骤：
薄荷用水蒸气蒸馏法提取挥发油，蒸馏后的水溶液另器保存；药渣与其余麻黄等八味，加水煎煮二次，每次1小时，第1次8倍量的水，第2次6倍量的水，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为90℃时为1.18～1.20的清膏；所得挥发油用适量β-环糊精包结，加适量清膏调色，喷雾干燥；清膏加入蔗糖1.7～2.3重量份、糊精1.7～2.3重量份，混匀、制粒、干燥、整粒，将挥发油包结物加入于干颗粒中，混匀，制成颗粒；或加入蔗糖1.7～2.3重量份、糊精1.7～2.3重量份、阿司帕坦0.06重量份，混匀，制粒、干燥、整粒，将挥发油包结物加入于干颗粒中，混匀，制成颗粒，即得。
本发明的有益效果是：
本发明开辟了药物组合物的新用途，帮助西医抗菌的准确用药提供精准药物。
本发明的药物组合物体外抗菌效果较好，其中对铜绿假单胞菌、痢疾杆菌、变形杆菌三种菌株的MIC为6.25mg/ml。对金葡菌、大肠埃希菌MIC为3.12mg/ml。体内抗菌结果表明，本发明的药物组合物可使腹腔感染金葡菌、痢疾杆菌、变形杆菌的小鼠的死亡率明显降低，保护率明显提高(P＜0.05或0.01)，对感染大肠埃希菌和铜绿菌的小鼠亦有一定的保护作用。
下述实验例和实施例用于进一步说明，但不限于本发明。
实验例1：体外抗菌实验
1.实验材料
1.1动物
昆明种小鼠，雄性，体重12～15g，山东鲁抗实验动物中心提供，生产许可证号：SCXK(鲁)20130001。
1.2实验菌种
金黄色葡萄球菌ATCC6538，大肠埃希菌(临床分离2株)，铜绿假单胞菌(临床分离2株)，福氏志贺菌(临床分离2株)，变形杆菌CMCC(B)49005，均为标准菌株，山东中医药大学微生物教研室提供。
1.3药品及主要试剂
苦甘颗粒(按照实施例6的方法制成，4g/袋，批号：140112)；生理盐水(山东克伦药业有限公司)；青霉素(北京悦康凯悦制药有限公司，06121005)；链霉素(北京悦康凯悦制药有限公司，08111103)；庆大霉素(北京悦康凯悦制药有限公司，09021012)
1.4仪器
96孔培养板；MK3酶标仪；全自动高压灭菌锅；超净工作台2.1供试品的制备：取苦甘颗粒4g，加70％乙醇50ml，超声20min，4℃下静置24小时，取上清液，回收乙醇，药液加水稀释至80ml，备用。(相当于苦甘颗粒50mg/ml)。
2.2体外抑菌实验：参照NCCLS标准采用微量稀释法进行。取灭菌96孔板，双倍稀释法用MH肉汤培养基稀释2.1.1项下供试品药液，同样方法接种到含1mg/ml双抗(青霉素、链霉素)培养基孔内，作为阳性药对照管；接种到不含药液的培养基孔内，作为菌液对照管；另设立不接种的含50mg/ml受试药培养基对照孔，37℃培养24h，酶标仪600nm波长下检测OD值，以确定细菌无生长的最低抑菌浓度。
2.3实验结果：
体外抗菌实验苦甘颗粒体外抗菌效果较好，其中对铜绿假单胞菌、痢疾杆菌、变形杆菌三种菌株的MIC为32.34mg/ml。对金葡菌、大肠埃希菌MIC为64.69mg/ml，见表1。
表1苦甘的体外抑菌活件(n＝2)
实验例2：体内抗菌实验
1最小致死菌量(MLD)的测定
将细菌种到普通肉汤培养基中培养18h后，进行细菌计数，4℃保存待用。选取健康昆明种小鼠，随机分为6组，每组8只，分别为5个菌液稀释组和一个空白组。每组分别腹腔注射生理盐水溶液稀释的菌溶液(稀释浓度分别为10-1、10-2、10-3、10-4)1ml，感染后观察并记录48h内小鼠死亡数，已引起小鼠80％～100％死亡的最低剂量作为MLD，用该剂量作为体内保护实验的感染剂量。
2细菌感染小鼠保护试验
按细菌种类分组，每组选取健康小鼠90只，体重12～15g，随机分为6组，即空白对照组、模型对照组、庆大霉素(青霉素)对照组、苦甘大剂量组0.986ml/g(相当于临床用量的2倍)，中剂量组0.4930ml/g(相当于临床用量)，小剂量组0.2460ml/g(相当于临床用量的1/2倍)。各组动物按剂量连续灌胃给药7d(空白和模型组给予等剂量生理盐水，庆大霉素对照组染菌前一天给药1次)，1次/天。第5天给药30分钟后选用2.2.1项下细菌浓度小鼠腹腔注射给药1ml，造成感染(空白组注射等剂量生理盐水)。观察7天内各组小鼠死亡数。采用SPSS13.0统计学软件对数据进行处理，p＜0.05为差异有统计学意义。
3结果
3.1不同细菌MLD测定结果见表2
表2不同细菌MLD测定结果
3.2细菌感染小鼠保护实验实验结果表明，苦甘颗粒可使腹腔感染金葡菌、痢疾杆菌、变形杆菌的小鼠的死亡率明显降低，保护率明显提高(P＜0.05或0.01)，对感染大肠埃希菌和铜绿菌的小鼠亦有一定的保护作用，结果见表3。
表3苦甘颗粒对细菌感染小鼠死亡数的影响(n＝15)
注：＊＊P＜0.01，*P＜0.05
具体实施方式：
实施例1：片剂的制备
麻黄6k，薄荷5kg，蝉蜕5kg，金银花15kg，黄芩12kg，苦杏仁9kg，浙贝母6kg，，桔梗6kg，甘草5kg；按常规方法加入常规敷料制成片剂。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
实施例2：胶囊剂的制备
麻黄3kg，薄荷9kg，蝉蜕3kg，金银花17kg，黄芩9kg，苦杏仁16kg，浙贝母3kg，桔梗8kg，甘草4kg。按常规方法加入常规敷料制成胶囊剂。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
实施例3：口服液体制剂的制备
麻黄9kg，薄荷2kg，蝉蜕7kg，金银花11kg，黄芩18kg，苦杏仁7kg，浙贝母7kg，桔梗4kg，甘草8kg。按常规方法加入常规敷料制成口服液体制剂。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
实施例4：
薄荷用水蒸气蒸馏法提取挥发油，蒸馏后的水溶液另器保存；药渣与其余麻黄等八味，加水煎煮二次，每次1小时，第1次8倍量的水，第2次6倍量的水，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.18～1.20(90℃)的清膏；清膏加入蔗糖200.89g、糊精200.89g，混匀、制粒、干燥、整粒，喷入挥发油，混匀，制成颗粒1000g；或加入蔗糖200.89g、糊精200.89g、阿司帕坦6g混匀，制粒、干燥、整粒，混匀，制成颗粒，即得。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
患者服用，一次2袋，一日3次。每袋4g
实施例5：滴丸的制备
麻黄500g，薄荷416.7g，蝉蜕416.7g，金银花1250g黄芩1000g，苦杏仁750g，浙贝母500g，
以上九味，薄荷用水蒸气蒸馏法提取挥发油，蒸馏后的水溶液另器保存；药渣与其余麻黄等八味，加水煎煮二次，第1次8倍量的水，第2次6倍量的水，每次1小时，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.18～1.20(90℃)的清膏；按常规方法制成滴丸。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
实施例6：
麻黄6kg，薄荷5kg，蝉蜕5kg，金银花15kg，黄芩12kg，苦杏仁9kg，浙贝母6kg，，桔梗6kg，甘草5kg；以上九味，薄荷用水蒸汽蒸馏法提取挥发油，蒸馏后的水溶液另器保存，药渣与其余麻黄等八味，加水煎煮二次，每次1小时，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.23-1.25(90-95℃)的清膏，取清膏1份，加蔗糖0.16份，糊精0.16份，混匀，制成颗粒，干燥，喷入上述挥发油，混匀，即得。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
实施例7：
麻黄3kg，薄荷9kg，蝉蜕3kg，金银花17kg，黄芩9kg，苦杏仁16kg，浙贝母3kg，桔梗8kg，甘草4kg。以上九味，薄荷用水蒸气蒸馏法提取挥发油，蒸馏后的水溶液另器保存；药渣与其余麻黄等八味，加水煎煮二次，每次1小时，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.18～1.20(90℃)的清膏；清膏加入蔗糖、糊精各2kg，混匀、制粒、干燥、整粒，喷入挥发油，混匀，制成颗粒；或加入蔗糖、糊精各2kg、阿司帕坦0.05kg混匀，制粒、干燥、整粒，混匀，制成颗粒，即得。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
实施例8：
麻黄9kg，薄荷2kg，蝉蜕7kg，金银花11kg，黄芩18kg，苦杏仁7kg，浙贝母7kg，桔梗4kg，甘草8kg。以上九味，薄荷用水蒸气蒸馏法提取挥发油，蒸馏后的水溶液另器保存；药渣与其余麻黄等八味，加水煎煮二次，每次1小时，第1次8倍量的水，第2次6倍量的水，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.18～1.20(90℃)的清膏；清膏加入蔗糖、糊精各1.9kg，混匀、制粒、干燥、整粒，喷入挥发油，混匀，制成颗粒；或加入蔗糖、糊精各1.9kg、阿司帕坦0.04kg混匀，制粒、干燥、整粒，混匀，制成颗粒，即得。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
实施例9：
麻黄9kg，薄荷2kg，蝉蜕7kg，金银花11kg，黄芩18kg，苦杏仁7kg，浙贝母7kg，桔梗4kg，甘草8kg。以上九味，薄荷用水蒸气蒸馏法提取挥发油，水溶液另器保存；药渣与其余麻黄等八味，加水煎煮二次，每次1小时，第1次10倍量的水，第2次8倍量的水，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.18～1.20(90℃)的清膏；所得挥发油用适量β-环糊精包结，加适量清膏调色，喷雾干燥；清膏加入蔗糖、糊精各2kg，混匀、制粒、干燥、整粒，将挥发油包结物加入于干颗粒中，混匀，制成颗粒；或加入蔗糖、糊精各2kg、阿司帕坦0.06kg混匀，制粒、干燥、整粒，混匀，制成颗粒，即得。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
实施例10：
麻黄3kg，薄荷9kg，蝉蜕3kg，金银花17kg，黄芩9kg，苦杏仁16kg，浙贝母3kg，桔梗8kg，甘草4kg。以上九味，薄荷用水蒸气蒸馏法提取挥发油，水溶液另器保存；药渣与其余麻黄等八味，加水煎煮二次，每次1小时，第1次8倍量的水，第2次6倍量的水，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.18～1.20(90℃)的清膏；所得挥发油用适量β-环糊精包结，加适量清膏调色，喷雾干燥；清膏加入蔗糖、糊精各1.76kg，混匀、制粒、干燥、整粒，将挥发油包结物加入于干颗粒中，混匀，制成颗粒；或加入蔗糖、糊精各1.76kg、阿司帕坦0.06kg混匀，制粒、干燥、整粒，混匀，制成颗粒，即得。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
实施例11：
麻黄6kg，薄荷5kg，蝉蜕5kg，金银花15kg，黄芩12kg，苦杏仁9kg，浙贝母6kg，，桔梗6kg，甘草5kg；以上九味，薄荷用水蒸气蒸馏法提取挥发油，水溶液另器保存；药渣与其余麻黄等八味，加水煎煮二次，每次1小时，第1次8倍量的水，第2次6倍量的水，合并煎液，滤过，滤液与上述水溶液合并，浓缩至相对密度为1.18～1.20(90℃)的清膏；所得挥发油用适量β-环糊精包结，加适量清膏调色，喷雾干燥；清膏加入蔗糖、糊精各2.1kg，混匀、制粒、干燥、整粒，将挥发油包结物加入于干颗粒中，混匀，制成颗粒；或加入蔗糖、糊精各2.1kg、阿司帕坦0.06kg混匀，制粒、干燥、整粒，混匀，制成颗粒，即得。用于抗菌感染，细菌种类为：金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、福氏志贺菌、变形杆菌。
Claims (4)
1.一种治疗感冒的药物组合物在制备抗菌的药物中的应用，所述药物组合物的原料药组成为：麻黄6kg，薄荷5kg，蝉蜕5kg，金银花15kg，黄芩12kg，苦杏仁9kg，浙贝母6kg，桔梗6kg，甘草5kg；取上述原料药，加入常规辅料，按照常规工艺，制成临床可接受的片剂、颗粒剂、丸剂、胶囊剂、缓释剂、口服液体制剂或冻干粉针剂；所述菌为福氏志贺菌。
2.如权利要求1所述的一种治疗感冒的药物组合物在制备抗菌的药物中的应用，其特征在于，所述颗粒剂的制备方法包括如下步骤：以上九味，薄荷用水蒸气蒸馏法提取挥发油，蒸馏后的水溶液另器保存，药渣与其余麻黄等八味，加水煎煮二次，每次1小时，合并煎液，滤过，滤液与上述水溶液合并，浓缩至90-95℃下相对密度为1.23-1.25的清膏，取清膏1份，加蔗糖0.16份，糊精0.16份，混匀，制成颗粒，干燥，喷入上述挥发油，混匀，即得。
3.如权利要求1所述的一种治疗感冒的药物组合物在制备抗菌的药物中的应用，其特征在于，所述丸剂为滴丸。
4.如权利要求1所述的一种治疗感冒的药物组合物在制备抗菌的药物中的应用，其特征在于，所述胶囊剂为软胶囊剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510866699.4A CN105412535B (zh) | 2015-11-30 | 2015-11-30 | 一种治疗感冒的药物组合物在制备抗菌的药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510866699.4A CN105412535B (zh) | 2015-11-30 | 2015-11-30 | 一种治疗感冒的药物组合物在制备抗菌的药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105412535A CN105412535A (zh) | 2016-03-23 |
| CN105412535B true CN105412535B (zh) | 2021-04-16 |
Family
ID=55491382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510866699.4A Active CN105412535B (zh) | 2015-11-30 | 2015-11-30 | 一种治疗感冒的药物组合物在制备抗菌的药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412535B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107890512A (zh) * | 2017-12-08 | 2018-04-10 | 湖南康寿制药有限公司 | 麻杏宣肺组合物、颗粒、饮品及制备方法 |
| CN109381595A (zh) * | 2018-10-10 | 2019-02-26 | 湖南康寿制药有限公司 | 一种麻杏宣肺中药组合物及其制备方法 |
| CN110664927A (zh) * | 2019-11-11 | 2020-01-10 | 上海医药集团青岛国风药业股份有限公司 | 一种治疗感冒的药物组合物及其制备方法、检测方法 |
| CN113244166A (zh) * | 2021-05-17 | 2021-08-13 | 南京正亮医药科技有限公司 | 一种治疗鼻炎的凝胶剂和口服制剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919961A (zh) * | 2009-06-10 | 2010-12-22 | 青岛国风药业股份有限公司 | 一种治疗感冒的药物组合物及其制备方法 |
-
2015
- 2015-11-30 CN CN201510866699.4A patent/CN105412535B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919961A (zh) * | 2009-06-10 | 2010-12-22 | 青岛国风药业股份有限公司 | 一种治疗感冒的药物组合物及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 板蓝根颗粒和苦甘颗粒对流感病毒感染小鼠的保护作用研究;翟志光等;《世界中西医结合杂志》;20111231;第6卷(第11期);987-989 * |
| 苦甘颗粒联合抗生素治疗外感咳嗽临床观察;焦西安等;《山西中医》;20131231;第29卷(第12期);18，25 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105412535A (zh) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105412535B (zh) | 一种治疗感冒的药物组合物在制备抗菌的药物中的应用 | |
| CN114502184A (zh) | 防治冠状病毒感染的包括杜英萃取物的药物和食品组合物 | |
| CN114053343A (zh) | 一种中药组合物、制备方法及应用 | |
| CN102600383B (zh) | 一种家禽用中草药制剂及其用途 | |
| KR20200003993A (ko) | 쪽잎 추출물을 포함하는 항균 조성물 및 이의 용도 | |
| Asoso et al. | Antibacterial activities of plantain (Musa paradisiaca) peel and fruit | |
| CN102688332A (zh) | 一种治疗感冒的中药组合物及其制备方法 | |
| CN102318746B (zh) | 一种用于细菌性畜禽疾病的动物保健品 | |
| Arekemase et al. | Assessment of Bitter leaf (Vernonia amygdalina) on some selected pathogenic microorganisms from University of Ilorin Teaching Hospital | |
| CN113350440B (zh) | 一种中药组合物在制备抗菌药物中的应用 | |
| KR102468406B1 (ko) | 대마 추출물을 유효성분으로 포함하는 항균 및 항바이러스 조성물 | |
| CN103933350B (zh) | 白及乙酸乙酯提取物的用途 | |
| CN102258635A (zh) | 一种兽用抗菌中药 | |
| CN107260774A (zh) | 蜡梅属植物抗致病菌感染的用途 | |
| CN102068464B (zh) | 六神曲抗菌、抗病毒有效部位提取物及其医药用途 | |
| CN101085037B (zh) | 一种兽用中药制剂及其制备方法 | |
| CN109700832A (zh) | 包含地衣芽孢杆菌和美洲大蠊提取物的药物组合物 | |
| CN101248837B (zh) | 一种植物抗菌抗禽流感功能性饲料添加剂 | |
| CN109646546B (zh) | 一种用于防治牲畜腹泻的中药组合物及其制备方法 | |
| CN102416050B (zh) | 一种用于治疗大肠杆菌病的兽药制剂及其制备方法 | |
| CN101366852B (zh) | 治疗鸭疫里氏杆菌病的中草药物及其制备方法 | |
| CN104688883B (zh) | 一种含地锦草苦参和黄芩的中药组合物及其制备方法 | |
| CN110404006A (zh) | 一种治疗鸡坏死性肠炎的药物组合物 | |
| Idrus | The Role of Sapodilla Fruit on Salmonella Typhi | |
| CN108926585A (zh) | 腊梅属植物提取物在制药中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |